Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant

被引：2
|
作者：
Peled, Jonathan U. [1 ]
Jenq, Robert R. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Adult Bone Marrow Transplantat Serv, 1275 York Ave, New York, NY 10021 USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 04期
基金：
美国国家卫生研究院;
关键词：
ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC-CELL TRANSPLANTATION; RELAPSE RISK EVIDENCE; NON-HODGKIN-LYMPHOMA; CYTOMEGALOVIRUS-INFECTION; T-CELLS; NK CELLS; ALLO-SCT; REACTIVATION; DONOR;
D O I：
10.1080/10428194.2016.1239265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：759 / 761
页数：3
相关论文
共 50 条
  • [41] Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD
    Damlaj, Moussab
    Snnallah, Mohammad
    Bashir, Razan
    Eddine, Inaam Shehab
    Alahmari, Bader
    Salama, Hind
    Alaskar, Ahmed
    Alhejazi, Ayman
    Alzahrani, Mohsen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (10): : 690 - 696
  • [42] CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia
    Green, Margaret L.
    Leisenring, Wendy M.
    Xie, Hu
    Walter, Roland B.
    Mielcarek, Marco
    Sandmaier, Brenda M.
    Riddell, Stanley R.
    Boeckh, Michael
    BLOOD, 2013, 122 (07) : 1316 - 1324
  • [43] THE INCIDENCE OF RECURRENCE OF LEUKEMIA IN DONOR CELLS AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
    BOYD, CN
    RAMBERG, RC
    THOMAS, ED
    LEUKEMIA RESEARCH, 1982, 6 (06) : 833 - 837
  • [44] QUANTIFYING ANTI-CYTOMEGALOVIRUS (CMV) IMMUNITY WITH CMV ANTIGEN SPECIFIC T CELLS (CASTS) AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLOHCT)
    Chen, G.
    Hahn, T.
    Zhang, Y.
    Pan, D.
    Brix, L.
    Ross, M.
    Liu, H.
    Wallace, P.
    McCarthy, P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S274 - S274
  • [45] Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?
    J Mehta
    R Powles
    B Sirohi
    J Treleaven
    S Kulkarni
    R Saso
    D Tait
    S Singhal
    Bone Marrow Transplantation, 2002, 29 : 853 - 859
  • [46] Monitoring of the graft vs leukemia (GVL) effect in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after allogeneic hematopoietic stem cell transplant (AlloHSCT)
    Isaacson, T. V.
    Krijanovski, O. I.
    Finn, W. G.
    LABORATORY INVESTIGATION, 2007, 87 : 246A - 247A
  • [47] Monitoring of the graft vs leukemia (GVL) effect in chronic lymphocytic Leukemia/Small lymphocytic lymphoma (CLL/SLL) after allogeneic hematopoietic stem cell transplant (AlloHSCT)
    Isaacson, T. V.
    Krijanovski, O. I.
    Finn, W. G.
    MODERN PATHOLOGY, 2007, 20 : 246A - 247A
  • [48] The significance of pre-transplant cytomegalovirus (CMV) serostatus for viral reactivation after allogeneic stem cell transplantation
    Petrov, Yavor
    Ganeva, Penka
    Arnaudov, Georgi
    Tonev, Ivan
    Simeonov, Stanislav
    Mincheff, Milcho
    Balatzenko, Georgui
    Alexandrova, Dora
    Jagurinoski, Milan
    Guenova, Margarita
    Spassov, Branimir
    BONE MARROW TRANSPLANTATION, 2018, 53 : 591 - 592
  • [49] Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma
    Koldehoff, Michael
    Ross, Stefan R.
    Duehrsen, Ulrich
    Beelen, Dietrich W.
    Elmaagacli, Ahmet H.
    LEUKEMIA & LYMPHOMA, 2017, 58 (04) : 822 - 833
  • [50] Late onset of EBV-driven PTLD/Burkitt lymphoma/leukemia in a patient 10 years after allogeneic stem cell transplant for AML
    Q Huang
    L Popplewell
    Y Lu
    M L Slovak
    S J Forman
    Bone Marrow Transplantation, 2010, 45 : 191 - 194
12345